Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
Kuhn, Deborah J; Berkova, Zuzana; Jones, Richard J; Woessner, Richard; Bjorklund, Chad C; Ma, Wencai; Davis, R Eric; Lin, Pei; Wang, Hua; Madden, Timothy L; Wei, Caimiao; Baladandayuthapani, Veerabhadran; Wang, Michael; Thomas, Sheeba K; Shah, Jatin J; Weber, Donna M; Orlowski, Robert Z.
; 120(16): 3260-70, 2012 Oct 18.
Artigo em Inglês | MEDLINE | ID: mdl-22932796
Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4<sup>CRBN</sup> activity.
BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
Panobinostat for the Treatment of Multiple Myeloma.
Glucocorticoids in multiple myeloma: past, present, and future.
Cytotoxic Properties of Damiana (<i>Turnera diffusa</i>) Extracts and Constituents and A Validated Quantitative UHPLC-DAD Assay.
The proteasome and proteasome inhibitors in multiple myeloma.
Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death.
Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade.
The role of long non-coding RNAs in multiple myeloma.
Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies.